What is SS-31 / elamipretide, and does the mitochondrial peptide actually work?

The short answer

SS-31, also known as elamipretide, is a mitochondria-targeting peptide that binds cardiolipin on the inner mitochondrial membrane to stabilize energy production. In September 2025 it earned FDA accelerated approval — as Forzinity — for one rare disease, Barth syndrome. But its Phase 3 trial for mitochondrial myopathy missed its primary endpoints, and there's no evidence for the "anti-aging energy boost" that gray-market SS-31 is sold for.

Evidence tier: Tier 1 for the approved Barth-syndrome indication and the failed myopathy trial; Tier 3 (no human evidence) for healthy-person "longevity" use. Educational content, not medical advice.

The key points:

• SS-31 = elamipretide — a real, now partly-approved mitochondrial drug
• Approved (2025) for Barth syndrome only — a rare genetic disorder
• Its Phase 3 mitochondrial-myopathy trial failed its primary endpoints
• No evidence for healthy "anti-aging" use — that's the gray-market pitch, not the data

For where this fits the longevity landscape, see longevity peptide stacks: what the evidence says.

What is SS-31 (elamipretide)?

Evidence tier: 1–2 — well-characterized mechanism.

SS-31 is a synthetic tetrapeptide, developed clinically as elamipretide (also seen as MTP-131 or bendavia), by Stealth BioTherapeutics. Its mechanism is genuinely distinct and elegant: it concentrates in mitochondria and binds cardiolipin, a lipid unique to the inner mitochondrial membrane. By stabilizing cardiolipin and the respiratory-chain "supercomplexes" that sit in that membrane, it's thought to improve electron-transport efficiency and reduce the leak of reactive oxygen species — in plain terms, helping struggling mitochondria make energy more cleanly.

Because mitochondrial dysfunction sits underneath so many conditions — rare genetic mitochondrial diseases, heart failure, eye disease, and the general decline of aging — a drug that directly targets the mitochondrial membrane drew enormous interest. That interest is exactly why "SS-31" also became a gray-market biohacker peptide, marketed for energy, recovery, and anti-aging. It's important to separate those two worlds from the start: elamipretide is a real clinical drug with a specific, hard-won evidence base, while gray-market "SS-31" is that same molecule sold and used far outside anything that's been tested. The rest of this walks through what's actually been shown.

What is SS-31 actually approved and proven for?

Evidence tier: 1 — FDA accelerated approval + trial data.

The landmark event: in September 2025 the FDA granted accelerated approval to elamipretide (brand name Forzinity) to improve muscle strength in patients with Barth syndrome weighing 30 kg or more — a rare, X-linked genetic disorder that impairs cardiolipin and devastates mitochondrial function (elamipretide Barth-syndrome approval review, 2025). This made it, in effect, the first therapy to directly target the mitochondrial membrane itself, and in the Barth trial program (TAZPOWER; ClinicalTrials.gov NCT03098797) knee-extensor muscle strength improved on treatment. That's a genuine, meaningful win for a devastating rare disease.

Two caveats keep this honest. First, it's an accelerated approval — a pathway that lets a drug reach a rare-disease population based on promising but not fully confirmatory data, with continued study required. Second, and crucially, the approval is narrow: it's for Barth syndrome, a specific genetic condition, not for mitochondrial dysfunction in general and certainly not for healthy people seeking an energy or longevity boost. So "SS-31 is FDA-approved" is true but easily misleading — it's approved for one rare disease, in a controlled pharmaceutical product, not as an anti-aging peptide.

Where has SS-31 fallen short?

Evidence tier: 1 — published Phase 3 trial.

This is the part the biohacker marketing skips. In primary mitochondrial myopathy — a broader mitochondrial-disease population — the pivotal Phase 3 trial, MMPOWER-3, did not meet its primary endpoints. Across 218 genetically confirmed patients randomized to elamipretide or placebo for 24 weeks, there was essentially no difference in the 6-minute walk test (−3.2 meters, p = 0.69) or in fatigue score (p = 0.37) (Neurology, MMPOWER-3, 2023). An earlier, smaller dose-finding study had hinted at a walking-distance benefit, but the large, rigorous Phase 3 didn't confirm it — a common and sobering pattern in drug development.

Other indications are still in progress rather than proven: heart-failure studies have shown short-term improvements in peak oxygen uptake, and dry age-related macular degeneration (geographic atrophy) has been explored, but none of these have delivered an approval. The honest summary is that elamipretide has a real mechanism, one narrow approval, one clear Phase 3 failure, and several open questions — a mixed clinical record, not a validated cure-all. That record is far more nuanced than "mitochondrial super-peptide," and the nuance matters when deciding whether the gray-market version is worth the risk.

Does SS-31 work for anti-aging or "mitochondrial health" in healthy people?

Evidence tier: 3 — no human evidence for this use.

Here's the direct answer: there is no clinical evidence that SS-31 improves energy, performance, recovery, or aging in healthy people. Every human trial has been in disease populations — Barth syndrome, mitochondrial myopathy, heart failure, eye disease — where mitochondria are pathologically impaired. Extrapolating from "may help a specific mitochondrial disease" to "will make a healthy 45-year-old feel more energetic and age slower" is a leap the data simply doesn't support, and the one large trial in a broad mitochondrial-disease group failed. The longevity case rests on mechanism and preclinical/aging-model work, not human outcomes — the same evidence gap we cover for the whole category in longevity peptide stacks and healthspan vs lifespan peptides.

That doesn't make the biology uninteresting — cardiolipin-targeting is a legitimately promising avenue, and it's plausible future research finds benefits in some aging contexts. But "promising mechanism" is where SS-31's anti-aging story currently ends. Anyone selling gray-market SS-31 as a proven energy or longevity peptide is describing a hypothesis as if it were a result. For how we grade exactly this kind of gap, see peptide evidence grades.

It's also worth naming why the "failed" myopathy trial matters for the longevity pitch specifically. Mitochondrial myopathy patients have measurably impaired mitochondria — arguably the population most likely to show a benefit from a mitochondrial drug. If a rigorous, well-powered trial couldn't demonstrate improved walking distance or fatigue there, the prior that the same molecule delivers a noticeable "energy boost" in already-healthy mitochondria is weak, not strong. The narrow Barth-syndrome win doesn't change that: Barth is a specific cardiolipin-remodeling defect the drug is almost tailor-made for, which is very different from ordinary aging.

What are the risks of gray-market SS-31?

Evidence tier: 2 — sourcing and use considerations.

The approved product, Forzinity, is a controlled pharmaceutical prescribed for a specific diagnosis under medical supervision. Gray-market "SS-31" is not that — it's the same molecule sold as an unapproved research peptide, typically for subcutaneous injection, with all the authenticity, purity, dosing, and contamination risks that apply to any gray-market injectable (spotting counterfeit peptides). You have no guarantee the vial contains genuine, correctly-dosed, sterile elamipretide, and you're using it for an indication (general "mitochondrial health") that has never been tested in people like you.

On tolerability, elamipretide's trial safety profile was relatively favorable — mainly mild injection-site reactions and headaches — which is reassuring about the molecule itself but says nothing about a random gray-market vial. The sensible framing: this is a real drug whose legitimate, evidence-backed use is narrow and clinician-supervised, and whose self-directed "longevity" use is unproven and sourced from an unregulated market. If mitochondrial or metabolic health is the actual goal, the proven levers — exercise (the single best mitochondrial stimulus), sleep, and nutrition — have vastly more evidence than an injectable peptide bought online.

Limitations

This is educational content, not medical advice.

• Approved only for Barth syndrome (accelerated approval, 2025) — not for general mitochondrial or anti-aging use.
• Phase 3 in mitochondrial myopathy failed its primary endpoints — a large, rigorous negative result.
• No human evidence in healthy people — the longevity case is mechanism/theory, not outcomes.
• Gray-market "SS-31" ≠ the approved product — authenticity, purity, dosing, and sterility risks apply.
• Trial safety looked favorable (injection-site reactions, headache), but that doesn't vouch for unregulated vials.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

SS-31 (elamipretide) is one of the more scientifically legitimate mitochondrial peptides — a cardiolipin-binding molecule with a genuine mechanism that, in September 2025, earned FDA accelerated approval as Forzinity for the rare disease Barth syndrome. But that's the whole of its proven human benefit: its large Phase 3 trial in mitochondrial myopathy missed its primary endpoints, and there is no clinical evidence it boosts energy, performance, or longevity in healthy people. The gray-market "SS-31" sold for anti-aging is the same molecule marketed far beyond what's been tested, from an unregulated supply. It's a fascinating drug to watch and a real therapy for a specific rare disease — not a validated longevity peptide, and not something to self-source on the strength of a mechanism story.

Related on this site

• Longevity peptide stacks: what the evidence says
• Healthspan vs lifespan peptides
• MOTS-c evidence guide
• Peptide evidence grades explained
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Elamipretide: the first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. 2025. PMID 41260682 — FDA accelerated approval and mechanism.
• Karaa A, et al. 2023. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. doi:10.1212/WNL.0000000000207402 — Phase 3 negative primary endpoints.
• A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER). ClinicalTrials.gov NCT03098797 — Barth-syndrome trial.